Member Info for LlamaFarmer

Billy same opinion.

Tried contacting BOD, they aren't interested, don't rate Wallbrook not proactive enough.

Sold, thanks for all the fish.

I was glad the sellers were here, added the last few I was after.

Protecting the IP like this is exactly what Solvonis have done in the USA, they have then spoken about licensing deals, Nasdaq listings etc.

It's an interesting stock with a very depressed share price and a suddenly promoting B.O.D. giving some newsflow and promising more all the ingredients you want in a small cap really.

GTC and EV man - thanks for the links.

Tonight was the start of the American arm of Solvonis.

Investors will approach Dennis to find out the names of these pharmas valued at under a hundred million but worth £300-375m for their phase 2 listing.

It gives us an idea of the Nasdaq listing price once SVN002 takes us towards a dual listing.

They highlighted that the Nassie has the best values for pharma stocks at the beginning of the presentation.

Is asked, Is Mental Health the next frontier?

I am at the stage of my career wheree I can work with who I want to and not put up with some of the problems that weve all dealt with over our careers.

Diseases that affect a lot of people, I got to look at Psychedelics, a lot of these phase 2 companies should ve valued at $400 - $500 ( £300 - £375m ) the data looks really good.

Jeremy Levin - Dennis said the industry needs investment, science is a desert, data I believe ( AI ) will drive an ignition across the board.

First:

I have done research into the scientific aspects of this company in great detail. The scientists involved behind the scenes are true innovators and pioneers in the therapeutic antibody field. They now have infinite resources & can invest in equipment that at one time was not affordable & within their reach. Pinpoint accuracy of antibodies, precision of targets and reproducibility in bulk are key in this game, fab now has the machinery to make that happen. Must also note that I am surprised the veterinary market branch hasn’t given us any news yet , that’s another huge under explored avenue for felinisation and caninisation of antibodies.

Second

Hi

Thanks for pointing out my grammatical error, apologies .These are all my own perceptions on the current state of play here at Fusion antibodies and I am confident in the end goal. I must profess I am no subject matter expert though so DYOR and background due diligence

Humpa - run it through an AI checker lol.

Vikr,

Ai is good to use but you should rewrite it and then spell check it ;)

GTC - thanks for those - this line stands out.

. To highlight this, we note the current

valuation of Absci (Nasdaq: ABSI), a larger US/Canadian-based firm that has an AI-led

approach to antibody drug design. This company has an EV of $275m (market

capitalisation of $386m and cash of $112m).

Vikr, it's the actual research from a pharma pro i'm interested in, do you have any? Here would be best but otherwise on Telegram? Thanks.

Hello Vikr,

It seems we both like Solvonis and Fusion Anti Bodies, I'd also recently taken MHC and Alien Metals ( UFO )

Cream of the crop for me is SVNS quality BOD and pipeline drugs, but F.A.B. does look very interesting.

If you have a lot of research notes would you mind putting them on here?

Other reason it does at least 100%, maybe 200% is that Boots will stock their own brand items in all stores with decent levels of each product!

Jamrock,

Yr post made me laugh, was me picking some up last few sessions, was trying to quietly build a position but there you go.

Two things,about my health I don't like.

1. No way to easily contact the BOD

2.Wallbrook P.R.

It's fine, retested the placing price, second 20% retest, back off it goes, bounced exactly on the dot.

Next stop 0.48/50p maybe more depending how Dennis Purcell gets on Tomorrow, 2am in New York, 7pm UK time.

Andy, thats a good lump, a few of us control a few percent of the company.

Are you in the telegram group?

Andy, how many you holding?

Https://www.businesswire.com/news/home/20250714485475/en/Exelixis-to-Release-Second-Quarter-2025-Financial-Results-on-Monday-July-28-2025

Mkt cap $12.43B

Ovid Therapeutics Market cap (intra-day)

$28.223M

Solvonis Market Cap $26.88M

Presenting:

Solvonis is advancing a differentiated pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet need.

The Company's lead programmes address Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD)-conditions affecting over 80 million people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in Europe and the UK. SVN-002 is preparing for a Phase 2b trial in the US targeting moderate to severe AUD. Solvonis also has a preclinical PTSD programme leveraging novel serotonin-dopamine modulators designed to enhance pro-social behaviour and long-term outcomes.

In addition, Solvonis is advancing an AI-supported discovery platform built on a proprietary CNS compound library, with initial focus on depression and stimulant use disorders. This initiative expands the Company's R&D pipeline into earlier-stage innovation while maintaining strategic focus on comorbid and underserved neuropsychiatric conditions.

With a capital-efficient model, dual development strategy, and near-term partnering opportunities, Solvonis is positioned to generate value through innovation in neuropsychiatry.

READ it again - NEAR TERM PARTNERING OPPORTUNITIES.

This is what Dennis is explaining to them;

Great pipeline products from Worlds top three pharma scientist in David Nutt.

Copyrighted material that lasts 95 years - Professor Celia Morgan.

Tightly controlled Finances under the leadership of Anthony Tennyson:

Before moving into the healthcare sector, Anthony worked in financial services. He spent ten years in international strategy and commercial leadership roles at Aon Plc and worked at Merrill Lynch and Bank of Ireland for five years. Anthony holds an MBA and an MSc from University College Dublin (UCD).

In the world of small cap investing, it is as they say, a no brainer.

I think they've been filling buy orders, will look for after hours later.

There's no buying going on - it's been NT for a while.

This won't go up in a straight line every day, but first of all it needs to rerate to somewhere near its true.

As JC01 pointed out now they have clearly signposted where this is going it is a safer bet to invest than ever before.

This is what will attract stronger and lasting investors - and its why I think we have this week to add in the 30's!

I think we have got this week to add in the 30's.

On Thursday Dennis is going to be highlighting their strong leadership and capital efficiency to American investors.

American investors en masse won't turn up until we have a dual Nasdaq listing but, some early bird investors will take a position and along with our volume should propel this to somewhere near a penny?